1. Differences in Outcomes Over Time With Exclusive Enteral Nutrition Compared With Steroids in Children With Mild to Moderate Crohn’s Disease: Results From theGROWTH CDStudy
- Author
-
Ron Shaoul, Malgorata Sladek, Sibylle Koletzko, Jorge Amil Dias, Javier Martín de Carpi, Annamaria Staiano, Rotem Sigall Boneh, Gábor Veres, Federica Nuti, Arie Levine, N. Cohen-Dolev, Seamus Hussey, Sivan Ben Avraham Shulman, Dan Turner, Tomer Ziv-Baran, Richard K. Russell, Anders Paerregaard, Tamar Pfeffer Gik, Paolo Lionetti, Chen Sarbagili Shabat, Cohen-Dolev, Noa, Sladek, Malgorata, Hussey, Seamu, Turner, Dan, Veres, Gabor, Koletzko, Sibylle, Martin de Carpi, Javier, Staiano, Annamaria, Shaoul, Ron, Lionetti, Paolo, Amil Dias, Jorge, Paerregaard, Ander, Nuti, Federica, Pfeffer Gik, Tamar, Ziv-Baran, Tomer, Ben Avraham Shulman, Sivan, Sarbagili Shabat, Chen, Sigall Boneh, Rotem, Russell, Richard K, and Levine, Arie
- Subjects
Male ,medicine.medical_specialty ,Pediatrics ,Adolescent ,Constriction, Pathologic ,Severity of Illness Index ,Gastroenterology ,Inflammatory bowel disease ,03 medical and health sciences ,Enteral Nutrition ,0302 clinical medicine ,Crohn Disease ,Adrenal Cortex Hormones ,Recurrence ,Internal medicine ,Severity of illness ,medicine ,Humans ,Rectal Fistula ,Prospective Studies ,030212 general & internal medicine ,Child ,Propensity Score ,Prospective cohort study ,Biological Products ,Crohn's disease ,business.industry ,Remission Induction ,Mean age ,General Medicine ,medicine.disease ,Abscess ,Body Height ,Treatment Outcome ,Parenteral nutrition ,Propensity score matching ,Female ,030211 gastroenterology & hepatology ,business ,Complication - Abstract
Background: Exclusive enteral nutrition [EEN] and corticosteroids [CS] induce similar rates of remission in mild to moderate paediatric Crohn's disease [CD], but differ with regard to mucosal healing. Our goal was to evaluate if EEN at diagnosis was superior to CS for improving long-term outcomes. Methods: We prospectively followed newly diagnosed children aged < 17 years, with mild to moderate CD at baseline, for 2 years in the GROWTH CD study. Patients were evaluated at baseline and at 8, 12, 78, and 104 weeks. Remission, relapses, complications [fibrostenotic disease, penetrating disease, and active perianal disease] and growth were recorded throughout the study. A propensity score analysis was performed. Results: A total of 147 children [mean age 12.9 +/- 3.2 years], treated by EEN [n = 60] or CS [n = 87] were included. New complications developed in 13.7% of CS [12/87] versus 11.6% of EEN [7/60], p = 0.29. Remission was achieved in 41/87 [47%] in CS and 38/60 [63%] EEN, p = 0.036. Median time to relapse did not differ [14.4 +/- 1 months with CS, 16.05 +/- 1.1 EEN, p = 0.28]. Mean height Z scores decreased from Week 0 to Week 78 with CS [-0.34 +/- 1.1 to -0.51 +/- 1.2, p = 0.01], but not with EEN [-0.32 +/- 1.1 to -0.22 +/- 0.9, p = 0.56]. In a propensity score analysis, EEN was superior to CS for inducing remission [p = 0.05] and trended to superiority for height Z score [p = 0.055]. Conclusions: Use of EEN was associated with higher remission rates and a trend toward better growth but with similar relapse and complication rates in new-onset mild to moderate paediatric CD.
- Published
- 2017
- Full Text
- View/download PDF